We will further study people who test positive for these early warning signs of multiple myeloma so that we can learn how to prevent them from developing into cancer.
This study aims to make multiple myeloma a cancer that is preventable.
Our Promise To Share Hope
Promise Study Introduction
The PROMISE Study - Principal Investigator Irene Ghobrial M.D.
Who can join and get screened at no cost?
2 groups of U.S. adults, age 30 or older, qualify for a free screening:
1. African Americans
AND / OR
2. People of Any Race Who Have a Parent, Sibling, or Child with:
Multiple myeloma, another blood cancer, OR one these related conditions:
We are also enrolling individuals who are 18 years of age or older and have a strong family history of blood cancer (2 or more first- and second-degree relatives).
Please sign up for the study if you qualify.
Note: The PROMISE study is for people who may have higher risks,
but have not been diagnosed with any of these conditions.
If you have been diagnosed with one of these conditions, please visit our PCROWD study, a sister project for people with precursor conditions.
Thank you for your interest in this mission. We encourage anyone to invite people who may qualify for a screening.
How do I join and get screened for free?
2. Accept Terms
Take a short survey and decide whether to go to the next step. We are fully committed to protecting your privacy. Study data is used only for research.
3. Receive Kit
Once you have completed the enrollment and are qualified for a free screening, we will send a collection kit to you at no cost.
When the kit arrives, it will contain instructions for how to schedule your free screening at a Quest Diagnostics lab near you, where they will collect a small amount of blood to be tested.
5. Get Results
We will check your blood sample for certain proteins that we call "precursor conditions" for multiple myeloma - a type of blood cancer.
We will notify all participants of their results. Everyone who participates is helping researchers find new ways to prevent and treat blood cancer.